Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Abstract 10: Contraindications to Oral Anticoagulation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
O’Brien, Emily C. , Koller, Christopher , Singer, Daniel E. , Ansell, Jack , Kowey, Peter R. , Chang, Paul, Ezekowitz, Michael D. , Piccini, Jonathan P. , Holmes, DaJuanicia N. , Allen, Larry A. , Hylek, Elaine M. , Gersh, Bernard J. , Fonarow, Gregg C. , Mahaffey, Kenneth W. , Peterson, Eric D.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 6 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.6.suppl_1.a10 Get It

Background. Oral anticoagulation therapy (OAC) reduces the risk of thromboembolic events associated with atrial fibrillation (AF), yet a substantial proportion of patients with AF are not prescribed OAC. The frequencies of and factors associated with contraindications to OAC therapy in clinical practice are not well-described. Methods. We used data from the ORBIT-AF study, a national, prospective, outpatient registry of incident and prevalent AF. OAC contraindications were uniformly collected at study enrollment by site personnel. Patient and provider characteristics were compared between participants with documented OAC contraindications at baseline and those without OAC contraindications. Results. From June 2010 to August 2011, 10124 patients ≥18 years old with electrocardiographically documented AF were enrolled at 176 practices. Of these, 1409 (13.9%) had OAC contraindications documented at the baseline visit: prior bleed (26.2%), patient refusal/preference (26.0%), high bleeding risk (22.6%), frequent falls/frailty (16.6%), other (11.9%), need for dual antiplatelet therapy (9.8%), unable to adhere/monitor warfarin (5.7%), comorbid illness (5.0%), prior intracranial hemorrhage (4.7%), allergy (2.3%), occupational risk (0.8%), and pregnancy (0.2%). Compared to patients without contraindications, those with contraindications had higher stroke risk (CHADS2>2) and were older, more likely to be female, more likely to be seen by a cardiologist and less likely to be seen by an electrophysiologist (Table 1). Among those patients with reported contraindications, 28.4% were taking warfarin. Conclusions. Contraindications to OAC therapy among AF patients are common and often due to high bleeding risk. Furthermore, many patients with reported contraindications are taking warfarin, suggesting that many contraindications to warfarin therapy are minor, relative, or temporary.
Abstract 10561: Attending Cardiac Rehabilitation Reduces Incidence of Dementia but Not Mild Cognitive Impairment in Patients with Coronary Artery Disease
Taylor, Jenna L. , Petersen, Ronald C. , Graff‐Radford, Jonathan , Johnson, Bruce D. , Bonikowske, Amanda R. , Taylor, Jenna L , Medina‐Inojosa, José R.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10561 Get It

Introduction: Coronary artery disease (CAD) has been associated with cognitive decline. Cardiac rehabilitation (CR) is a class 1A recommendation for patients with CAD as it reduces future cardiac events and mortality. However, the impact of CR on incidence of mild cognitive impairment (MCI) and dementia has not been extensively studied. We investigated the association of CAD on incidence of MCI and dementia; and whether CR attendance reduces incidence of MCI and dementia in patients with CAD Methods: The Mayo Clinic Study of Aging (MCSA), a prospective, population-based cohort was probed for this study. At baseline and every 15-months thereafter, subjects were evaluated for MCI and dementia using a standardized protocol. Data on CR participation were collected via record linkage to the Rochester Epidemiology Project. To evaluate association with incident MCI or dementia, cox proportional hazard models were used and adjusted for age, sex, and clinical predictors of cognitive decline. Participants with MCI at baseline were excluded for MCI analysis and adjusted for in dementia analysis. Results: We included 5960 MCSA participants (female: 50%; age: 70±13). Of those, 1934 participants (32%) had CAD and 702 (12%) had MCI at baseline. Mean follow-up was 3.9±3.7yrs, with 760 incident cases of MCI (13%) and 290 cases of dementia (5%). CAD was a significant predictor of MCI and dementia, although after adjustment for other clinical predictors, CAD was only associated with MCI incidence ( Table 1, Figure ). Incidence of dementia was reduced in CAD patients who had a greater attendance at CR when adjusted for other predictors of cognitive decline ( Table 2 ). Attendance at CR did not reduce incidence of MCI ( Table 2 ). Conclusions: CAD was a significant predictor of MCI and dementia. In patients with CAD, a higher attendance of CR was associated with reduced incidence of dementia but not MCI. Specific CR programming and outcome targets may be needed to prevent MCI in patients with CAD.
Abstract 10133: Cerebrovascular Imaging Biomarkers, Neuropsychiatric Symptoms, and Mild Cognitive Impairment
Vassilaki, Maria , Syrjanen, Jeremy A. , Graff‐Radford, Jonathan , Lowe, Val J. , Petersen, Ronald, Scharf, Eugene , Krell‐Roesch, Janina , Vemuri, Prashanthi , Mielke, Michelle M. , Machulda, Mary M. , Kremers, Walter K. , Jack, Clifford R. , Knopman, David S. , Petersen, Ronald, Geda, Yonas E.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10133 Get It

Introduction: Cerebrovascular disease (CVD) and neuropsychiatric symptoms (NPS) are common in older adults and are independently associated with cognitive impairment. In addition, vascular depression (a late-life depression) is hypothesized to be associated with cerebrovascular pathology. Hypothesis: CVD pathology imaging biomarkers (e.g., white matter hyperintensities (WMH), infarctions) are associated with depression and anxiety, and both (depression/anxiety and CVD imaging biomarkers) are independently associated with mild cognitive impairment (MCI). Methods: This cross-sectional study included 1739 Mayo Clinic Study of Aging participants (≥50 years old) without dementia, with comprehensive cognitive evaluations and available data on the Beck Depression Inventory II (BDI), the Beck Anxiety Inventory (BAI) and imaging CVD biomarkers via FLAIR-MRI (i.e., WMH% of total intracranial volume (TIV) and brain infarctions). We used linear and logistic regression models to examine the associations adjusting for age, sex, education, and apolipoprotein E ε4 status. Results: Participants’ mean age (SD) was 71.11 (10.61) years (53.3% males). Higher WMH% TIV burden was significantly associated with higher BDI (b= 0.082, 95%CI: 0.031, 0.133), p=0.002) and BAI scores (b= 0.088, 95%CI: 0.037, 0.140), p=0.001); the presence of infarctions was also associated with a higher BDI score. Both WMH %TIV burden (OR: 1.20 (95%CI:1.05, 1.38), p=0.008) and BDI score (OR: 1.38 (95%CI:1.21, 1.57), p<0.001) were significantly associated with MCI when included simultaneously in the model. We observed similar associations for CVD biomarkers and BAI score with MCI. Conclusions: CVD imaging biomarkers and NPS, as measured by BDI and BAI scores, could represent two distinct processes associated with cognitive impairment. Studies are ongoing to further examine these associations and delineate how CVD, NPS, and other pathophysiology processes (e.g., Alzheimer’s disease) interact and are associated with cognitive impairment.
Abstract 9992: Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Shrader, Peter, Piccini, Jonathan P. , Kowey, Peter R. , Reiffel, James A. , Thomas, Laine , Noheria, Amit , Fonarow, Gregg C. , Mahaffey, Kenneth W. , Naccarelli, Gerald V. , Noseworthy, Peter A. , Steinberg, Benjamin A. , Peterson, Eric D. , Gersh, Bernard J.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.9992 Get It

Introduction: Randomized trials have not demonstrated significant differences in stroke, heart failure or mortality between rhythm and rate control strategies for management of atrial fibrillation (AF). The comparative outcomes in contemporary clinical practice are not well described. The objective of this study was to evaluate outcomes in clinical practice with rhythm control versus rate control strategy. Methods: Patients managed with a rhythm control strategy targeting maintenance of sinus rhythm were retrospectively compared with a strategy of rate control alone in a AF registry across various US practice settings. Unadjusted and adjusted (inverse-propensity weighted) outcomes were estimated. Results: The overall study population (n=6988) had a median age of 74 (25th, 75th percentile 65, 81) years, 56% were males, 77% had first detected or paroxysmal AF and 89% had CHA2DS2-VASc score ≥2. In unadjusted analyses, rhythm control was associated with lower all-cause death, cardiovascular death, first stroke/non-central nervous system systemic embolization/transient ischemic attack, or first major bleeding event (all p<0.05); however, rhythm control was associated with more cardiovascular hospitalizations (HR 1.24, 95% CI 1.10-1.39, p=0.0003; Figure). Conclusion: Among patients with AF in clinical practice, rhythm control was not superior to rate control strategy for outcomes of stroke, heart failure, or mortality, but was associated with more cardiovascular hospitalizations.
Abstract 17225: Therapeutic Strategies Following Major Bleeding in Atrial Fibrillation: Findings From ORBIT-AF
O’Brien, Emily C. , Simon, DaJuanicia N., Ansell, Jack , Kowey, Peter R. , Piccini, Jonathan, Fonarow, Gregg C. , Gersh, Bernard J. , Mahaffey, Kenneth W. , Peterson, Eric D. , Piccini, Jonathan P. , Hylek, Elaine M.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.17225 Get It

Background: Little information exists on clinical characteristics and treatment patterns of patients with atrial fibrillation (AF) following a major bleeding event in clinical practice. Methods: We used data from a large, national outpatient registry, ORBIT-AF (2010 – 2011), to evaluate event characteristics and oral anticoagulation (OAC) management following a major bleeding event. Major bleeds were defined according to ISTH criteria. We compared baseline characteristics among patients who persisted on OAC therapy at the first clinic visit following a major bleed and those in whom OAC was discontinued using chi-squared tests. Results: Of 10135 patients enrolled in ORBIT-AF, n=791 (7.8%) bleeding events occurred during 2 years of follow-up. Among patients who were receiving OA, n=632 (3.5 per 100 person years) experienced a major bleed. Of these, 67.3% experienced a fall in hemoglobin and 46.8% required transfusion of 2 of more units of red blood cells. Critical site bleeding occurred in 150 OAC patients, with the majority of these classified as intracranial bleeding (n= 89), followed by retroperitoneal (n=25) and intraocular (n=17). Fatal bleeds occurred in 37 patients (5.9% of all major bleeds). Nearly one-third of patients (31.0%) discontinued OAC therapy following the major bleeding event. Compared with those who persisted on OAC, patients who discontinued OAC were more likely to have hypertension and CKD. Those who discontinued OAC were more likely to have gastrointestinal or CNS site bleeding compared with those who persisted (Table). Conclusions: One in three patients who experienced a major bleed were no longer optimally anticoagulated after the event. Those who discontinued OAC had a greater comorbidity burden and more likely to have bleeding in a critical site those who persisted on OAC.
Posterior cortical atrophy: Primary occipital variant
Shir, Dror , Graff‐Radford, Jonathan , Pham, Nha Trang Thu, Jack, Clifford R. , Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Whitwell, Jennifer , Josephs, Keith A , Jack, Clifford R , Shir, Dror , Machulda, Mary M.

Mayo Clinic

European Journal of Neurology | March 17, 2022 | Volume: 29 | Issue: 7 | Pages: 2138-2143

10.1111/ene.15327 | PMID 35298068 Get It

AbstractBackgroundPosterior cortical atrophy (PCA) is one of the atypical Alzheimer's disease variants, characterized by predominant visuospatial and visuoperceptual deficits, with established dorsal and ventral subtypes. A third primary occipital (caudal) variant has been suggested. We aimed to determine its demographics, clinical manifestations, and biomarker findings.MethodsFifty‐two PCA patients were investigated. Patients underwent neuropsychological assessment, magnetic resonance imaging, and fluorodeoxyglucose (FDG)‐, amyloid‐, and tau‐positron emission tomography (tau‐PET) scans. Normalized regional FDG‐PET values were represented as z‐scores relative to a control population. Patients were divided into “primary occipital” and “other PCA” subgroups according to FDG‐PET‐defined criteria, with primary occipital defined as patients in which the z‐scores for occipital subregions were at least one standard deviation lower (SD) (i.e., more abnormal) than the z‐scores in all other brain regions. Global amyloid‐PET, temporo‐parietal FDG‐PET, and temporal tau‐PET regions‐of‐interest (ROIs) were calculated.ResultsNine patients were classified as primary occipital; they were older (p = 0.034) and had more years of education (p = 0.007) than other PCA patients. The primary occipital group performed worse on the Ishihara test for color perception (p < 0.001), while other PCA patients performed worse on the Western Aphasia Battery (WAB) praxis scale (p = 0.005). Overall neuropsychiatric symptom burden was lower in the primary occipital group (p < 0.001). The FDG‐PET meta‐ROI was higher in the primary occipital subtype (p = 0.006), but no differences were observed in amyloid‐ and tau‐PET.ConclusionsOur findings suggest that primary occipital PCA is characterized by an older age at onset, more color perception dysfunction, less severe ideomotor apraxia, and less hypometabolism in temporo‐parietal meta‐ROI compared to established phenotypes.
Diagnosis of Primary Scrotal Lymphedema Using 99mTc-Sulfur Colloid Lymphoscintigram
Rhee, Annie, Casey, William J., Roarke, Michael C., Rebecca, Alanna M. , Flug, Jonathan A. , Yang, Ming

Mayo Clinic

Clinical Nuclear Medicine | March 16, 2022 | Volume: 47 | Issue: 5 | Pages: e417-e418

10.1097/rlu.0000000000004132 | PMID 35293355 Get It

Abstract We report a case of a 19-year-old man who presented with severe scrotal swelling. His medical history was notable for severe global edema at birth. Most areas of swelling had resolved by adolescence with exception of the scrotum and the left lower extremity. 99mTc-filtered sulfur colloid lymphoscintigraphy of the lower extremities demonstrated prominent dermal backflow into the superficial scrotum and thighs, which were confirmed on the SPECT/CT images, and correlated with findings on MR lymphangiogram. Lymphoscintigram and MR lymphangiogram may provide complementary information to aid diagnosis and management of primary scrotal lymphedema.
Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis
Ma, Christopher , Pai, Rish K. , Krell, Jonathan , Guizzetti, Leonardo , McFarlane, Stefanie C., MacDonald, John K, Choi, Won‐Tak , Feakins, Roger , Kirsch, Richard , Lauwers, Gregory Y. , Pai, Reetesh K. , Rosty, Christophe , Srivastava, Amitabh , Walsh, Joanna C. , Feagan, Brian G. , Ma, C , Guizzetti, L , Rosty, Christophe , Srivastava, Amitabh , Schaeffer, David F. , Jairath, Vipul

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 16, 2022 | Volume: 10 | Issue: 3 | Pages: e004560

10.1136/jitc-2022-004560 | PMID 35296560 Get It

Immune checkpoint inhibitor-associated colitis (ICIC) affects approximately 15% of cancer patients treated with immunotherapy. Although histological evaluation is potentially valuable for both the diagnosis of ICIC and evaluation of disease activity, use in clinical practice is heterogeneous. We aimed to develop expert recommendations to standardize histological assessment of disease activity in patients with ICIC. Using the modified Research and Development/University of California Los Angeles (RAND/UCLA) appropriateness methodology, an international panel of 11 pathologists rated the appropriateness of 99 statements on a 9-point Likert scale during two rounds of anonymous voting. Results were discussed between rounds using moderated videoconferences. There are currently no disease-specific instruments for assessing histological features of ICIC. The panel considered that colonoscopy with at least three biopsies per segment from a total of at least five segments, including both endoscopically normal and inflamed areas, was appropriate for tissue acquisition. They agreed that biopsies should be oriented such that the long axis of the colonic crypts is visualized and should be stained with hematoxylin and eosin. Histological items that the panel voted were appropriate to evaluate in ICIC included the degree of structural/architectural change, chronic inflammatory infiltrate, lamina propria and intraepithelial neutrophils, crypt abscesses and destruction, erosions/ulcerations, apoptosis, surface intraepithelial lymphocytosis, and subepithelial collagen thickness. The appropriateness of routine immunohistochemistry was uncertain. These expert recommendations will help standardize assessment of histological activity in patients with ICIC. The panel also identified the development and validation of an ICIC-specific histological index as a research priority.
PAPP-A Results Cannot Be Used to Accurately Estimate Gestational Age
Johnson, Lisa M., Genzen, Jonathan R. , Bornhorst, Joshua A. , Bornhorst, Joshua, Bornhorst, Joshua , Algeciras‐Schimnich, Alicia , Lambert-Messerlian, Geralyn M.

Mayo Clinic

The Journal of Applied Laboratory Medicine | March 15, 2022 | Volume: 7 | Issue: 4 | Pages: 1000-1002

10.1093/jalm/jfac020 | PMID 35661888 Get It

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ansell, Stephen M. , Barnes, Jeffrey A. , Brammer, Jonathan E. , Clemens, Mark W. , Ghione, Paola , Goodman, Aaron M. , Guitart, Joan , Haverkos, Bradley M. , Hoppe, Richard T. , Jacobsen, Eric D. , Jagadeesh, Deepa , Jones, Allison , Mehta–Shah, Neha , Olsen, Elise A. , Rajguru, Saurabh, Rozati, Sima , Said, Jonathan , Shaver, Aaron C., Shea, Lauren , Sokol, Lubomir , Wu, Peggy A. , Zain, Jasmine , Dwyer, Mary A., Sundar, Hema, Hoppe, Richard T , Ghione, Paola , Horwitz, Steven M. , Ai, Weiyun Z. , Barta, Stefan K , Doǧan, Ahmet , Foss, Francine M. , Halwani, Ahmad , Kallam, Avyakta , Kim, Youn H , Kumar, Kiran Achut , Shinohara, Michi M. , Sokol, Lubomir , Torres‐Cabala, Carlos A. , Wilcox, Ryan A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 11, 2022 | Volume: 20 | Issue: 3 | Pages: 285-308

10.6004/jnccn.2022.0015 | PMID 35276674 Get It

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic lymphoma kinase–positive, anaplastic large cell lymphoma, anaplastic lymphoma kinase–negative, and enteropathy-associated T-cell lymphoma. This discussion section focuses on the diagnosis and treatment of PTCLs as outlined in the NCCN Guidelines for T-Cell Lymphomas.